| Name | Title | Contact Details |
|---|
EYEVANCE Pharmaceuticals` mission is to develop and commercialize INNOVATIVE and IMPACTFUL ophthalmic products to enable optimal vision and better quality of life for all patients
Arrakis Therapeutics is a biopharmaceutical company pioneering the discovery of a new class of medicines that directly target RNA. Arrakis is building a proprietary pipeline of RNA-targeted small molecule (rSM) medicines focused on cancer and genetically validated targets in other disease areas. The company brings together scientific leaders in RNA structure, chemistry and biology, along with a highly experienced management team and the backing of leading life sciences investors. The company is located in Waltham, Massachusetts.
Allarity Therapeutics (Nasdaq: ALLR) is a clinical-stage precision medicine company actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. The company is leveraging its proprietary, highly accurate Drug Response Predictor (DRP®) technology to refine patient selection and improve clinical outcomes. Publicly traded on NASDAQ, Allarity (ALLR) is headquartered in Cambridge, MA, while maintaining an R&D facility in Hoersholm, Denmark. Allarity is committed to enhancing patient outcomes through improved decision-making and personalized cancer care.
Hysitron, Inc is a Eden Prairie, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Sterling is a CDMO or contract development and manufacturing organisation (/contract manufacturer organisation) with facilities in the UK and US.